Search company, investor...

Founded Year



Other Investors | Alive

About Minka Therapeutics

Minka Therapeutics was originally created to exploit the 3S/P44L platform and mechanism of actions in the treatment of HIV. Today, its science has broad applications in the field of infectious diseases and oncology.

Headquarters Location

28 rue de l'Amiral Hamelin

Paris, 75016,




Latest Minka Therapeutics News

Minka Therapeutics SA Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 27092018 Prices from USD $250

Oct 19, 2018

10:26 EDT 19 Oct 2018 | BioPortfolio Reports Summary Minka Therapeutics SAMinka Therapeutics formerly known as InnaVirVax SA, is a biopharmaceutical company which discovers and develops products for the treatment of HIV/AIDS infection pathologically and novel cancer therapies. The company's pipeline product portfolio comprise DIAG3S, an AIDS prognostic test; VAC3S, an HIV AIDs therapeutic vaccine protecting the cd4+ t lymphocytes from depletion; VAC02, a vaccine project for the prophylactic vaccination against HIV injection, and others. Minka Therapeutics works in collaboration with pharmaceutical companies, biotechnology companies and research institutes for the further development and commercialization of its vaccine candidates. The company develops a potent vaccine technology platform which can generate high levels of antibodies targeted against the used peptide antigens. Minka Therapeutics is headquartered in Evry, France. Minka Therapeutics SA Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News

Minka Therapeutics Frequently Asked Questions (FAQ)

  • When was Minka Therapeutics founded?

    Minka Therapeutics was founded in 2017.

  • Where is Minka Therapeutics's headquarters?

    Minka Therapeutics's headquarters is located at 28 rue de l'Amiral Hamelin, Paris.

  • What is Minka Therapeutics's latest funding round?

    Minka Therapeutics's latest funding round is Other Investors.

  • Who are the investors of Minka Therapeutics?

    Investors of Minka Therapeutics include Karista.



CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.